The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

Patients and caregivers The social, emotional and financial impact of Alzheimer's on patients and caregivers/family is devastating. Due to limited diagnostic and treatment options patients are ...

Alzheimer's disease begins with a long period during which abnormal amyloid and tau proteins build up in the brain without ...

It is believed most humans are ... First Successful Clinical Trial of VU319 Brings Alzheimer's Treatment One Step Closer Dec. 19, 2024 — Phase I clinical trial of a drug was successfully ...

For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...

Targeting toxic oligomers without binding to plaque, designed to reduce the risk of ARIA and potentially deliver enhanced ...

Beyond Kisunla, the company is developing remternetug, a next-generation Alzheimer’s treatment being tested as both an infusion and an injection. The late-stage trial will assess the ...

It is believed most humans are ... First Successful Clinical Trial of VU319 Brings Alzheimer's Treatment One Step Closer Dec. 19, 2024 — Phase I clinical trial of a drug was successfully ...

While some have praised the “wonderful news” as a “real success” for Alzheimer’s treatment ... the approval as offering “exciting new options” for patients. Several HCPs also ...

(RTTNews) - Wednesday, Johnson & Johnson (JNJ) announced that the FDA has granted Fast Track designation to its Posdinema, a monoclonal antibody being studied for treating early stage Alzheimer's ...

Genetic differences that contribute to how long a person will live and their risk of Alzheimer's disease have been identified by researchers at UCL and the UK Dementia Research Institute (UK DRI).